Dosage guide · 20 mg vial

Cartalax Dosage Protocol

Ala-Glu-Asp (AED/T-31) · experimental cartilage bioregulator

The reference protocol starts at 2 mg once daily for weeks 1–2, then moves to 3 mg, 4 mg and 5 mg in two-week steps. With 3 mL of bacteriostatic water, a 20 mg vial is 6.67 mg/mL, so the 2 mg start amount is 30 units (0.30 mL) on a U-100 syringe. Cartalax has no clinically established human dose.

How oftenOnce daily

Starting dose2 mg

Start = units30 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Cartalax 20 mg vial

Not currently stocked by Peak Peptides Australia

No product photo — this strength isn't stocked by Peak

Dosage chart How to mix Supplies Calculator About Cartalax References

01 · DOSAGE CHART

Cartalax dosage chart

Gradual daily approach · 20 mg vial + 3 mL BAC water

BAC water added

Concentration6.67 mg/mL

1 unit (U-100)66.7 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL is the reference protocol’s mix; it makes the 2–5 mg daily range 30–75 units.

Cartalax dosage chart for a 20 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units
Weeks 1–2Start	2 mg	30 units0.3 mL
Weeks 3–4	3 mg	45 units0.45 mL
Weeks 5–8	4 mg	60 units0.6 mL
Weeks 9–12Max	5 mg	75 units0.75 mL

Once daily · any consistent time · subcutaneous injection

The reference schedule increases by 1 mg every 2 weeks through week 9.

The published reference table ends after week 12; it does not establish a clinically validated cycle length.

Reference-site amounts only — Cartalax has no ARTG listing or clinically established human dose. Education only, not medical advice. Dose amounts adapted from Cartalax 20 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 20 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 6.67 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 6.67 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 20 mg vial mixed with 3 mL.

Length of protocol

10Cartalax 20 mg vials182 mg needed in total

661 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

3BAC water 10 mL bottles30 mL used for mixing

132Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

Concentration

6.67 mg/mL

(6667 mcg/mL)

Calculated Liquid Volume

0.300 mL

Equivalent U-100 volume scale position

30markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Cartalax

Protocol overview

Starting dose: 2 mg once daily for weeks 1–2
How it increases: 3 mg in weeks 3–4, 4 mg in weeks 5–8, then 5 mg in weeks 9–12
Frequency: Once daily
When to take it: Any consistent time in the reference protocol
Reference duration: 12 weeks in the source table
Common mix: 3 mL bacteriostatic water → 6.67 mg/mL; 2 mg = 30 units

Storage

Before mixing: The reference protocol says to refrigerate at 2–8 °C or freeze at −20 °C for long-term storage, protected from light.
After mixing: Keep at 2–8 °C and protected from light; follow the product label’s use-by instructions.
Never: Avoid repeated freeze–thaw cycles or using a solution that is cloudy or has particles.

How it works

Cartalax is the short synthetic tripeptide Ala-Glu-Asp, also called AED or T-31. It is discussed in laboratory research on short peptide bioregulators and cartilage-related cell processes.

In cell and animal models, AED has been reported to alter markers of cell proliferation, extracellular-matrix remodelling and cellular ageing. Those findings do not show that it repairs cartilage or treats joint disease in people.

Illustrated mechanism explainer

What the research shows

A 2023 review describes AED as one of the short peptides found in a cartilage-derived polypeptide complex; the review discusses AED effects in mesenchymal-stem-cell ageing models, not a human Cartalax dosing study.
A 2016 in-vitro fibroblast paper found that AED and AEDG suppressed caspase-dependent apoptosis, while the peptides studied reduced MMP-9 synthesis and increased Ki-67 and CD98hc expression in ageing cultures.
The PubMed search for Cartalax returned 6 records, including cell-culture and animal-related papers; the listed results did not provide a clinically established human Cartalax dose.
The ARTG search returned no matching result for Cartalax, so it should not be represented as a TGA-approved medicine in Australia.

Reported side effects

A controlled human adverse-effect profile and a clinically established human dose for isolated Cartalax were not identified in the sources reviewed.
Cell-culture and animal findings cannot predict human safety, interactions, allergy risk or long-term effects.
A research peptide supplied outside an approved medicine system also raises identity, potency, sterility and contamination concerns.

Important notes

The ARTG search returned no Cartalax listing; do not describe it as a TGA-approved medicine in Australia.
WADA status: Cartalax is not named in the 2026 List, but WADA S0 prohibits pharmacological substances with no current approval by any governmental regulatory health authority at all times. Athletes should obtain advice from their anti-doping organisation.
There is no clinically established human Cartalax dose; the chart reproduces the referenced educational protocol rather than a medical label or human dose-finding result.
Peak does not stock Cartalax, so this page is a reference for a 20 mg vial and has no shop link.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

Cartalax questions

How many units is 2 mg of Cartalax?

With the default 3 mL mix in a 20 mg vial, the concentration is 6.67 mg/mL. A 2 mg amount is 30 units, or 0.30 mL, on a U-100 syringe.

How much bacteriostatic water for a 20 mg Cartalax vial?

The reference protocol and default selector use 3 mL. That gives 6.67 mg/mL, where 1 mg is 15 units (0.15 mL) on a U-100 syringe.

How many units is 5 mg of Cartalax?

With 3 mL in a 20 mg vial, 5 mg is 75 units, or 0.75 mL, on a U-100 syringe.

How long does a 20 mg Cartalax vial last?

At 2 mg once daily, a 20 mg vial provides 10 daily amounts. At 3 mg it provides 6 full daily amounts with 2 mg remaining; at 4 mg it provides 5 days, and at 5 mg it provides 4 days.

07 · SOURCES